JHEPATOL: Impact factor 25.7 The Journal of Hepatology has solidified its status as the premier hepatology-only journal. It has managed to improve its standing in the highly competitive Gastro-Hep category, securing the fourth position within this category. This accomplishment, under…
Join the EASL Scientific Committee EASL is now calling for applications for one new member to join the Scientific Committee. The term for these members is from October 2023 to October 2026.
Steatotic liver disease (SLD) is new overarching term with metabolic dysfunction-associated steatotic liver disease (MASLD) replacing nonalcoholic fatty liver disease (NAFLD) Vienna, Austria, June 24 - At EASL Congress 2023, the multinational liver societies leaders from La Asociación Latinoamericana para…
In recognition of her outstanding dedication and commitment to patient care, Marta Carol Perdiguer has been honoured with the "Rising Star 2023" award. This prestigious accolade highlights emerging liver nurses and Allied Health Professionals (AHPs) who prioritise the well-being of…
DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well-characterized patient cohorts. The ultimate goal is to significantly reduce mortality…
David Pinato and Lung Yi Mak have been awarded the prestigious EASL Emerging Leader Award, recognizing their outstanding contributions to liver research. The award, presented annually at the EASL Congress, is dedicated to young fellows who have made significant advancements…
Collaborating with multinational liver societies, patient advocacy groups, and leading experts and researchers, a global consortium will unveil a new nomenclature for the prevalent Non-Alcoholic Fatty Liver Disease (NAFLD) at the upcoming EASL Congress in Vienna on 21-24 June. This…
The A-TANGO consortium performs Phase 2 clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. This novel combinatorial therapy is called G-TAK. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and…
MICROB-PREDICT aims to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual…
Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) funded by the European Innovative Medicines Initiative 2 Joint Undertaking, brings together clinicians and scientists from prominent academic centres across Europe with companies from the European Federation of Pharmaceutical Industries and Associations…